Kieran Deane-Alder

Kieran is a PhD candidate at the Monash Institute of Pharmaceutical Sciences in Victoria, Australia. His research focuses on using structural biology methods to understand the diverse pharmacology of G protein-coupled receptors, with a particular focus on partial agonists of the cannabinoid receptors, such as THC. Prior to this, he obtained a Masters in Pharmacology from the University of Auckland, New Zealand, investigating the clinical toxicology of rare adverse drug reactions to the antipsychotic drug clozapine. Kieran is deeply interested in all aspects of psychoactive compounds, from fundamental biochemistry to clinical safety.

Articles by Kieran Deane-Alder

5-HT2A Virtual Chemical Screen Produces New Candidate Antidepressants

November 10, 2022 - - 1 Comment

The serotonin receptor subtype 5-HT2A is key for the effects of many psychedelic substances in humans, but it is also a major drug target for new antidepressants. However, large challenges have prevented this therapeutic promise from being realised. Overcoming the early bottlenecks, innovative drug discovery methods have produced two new compounds with potential for therapeutic development.